Tag: Boehringer Ingelheim

Merck, Bayer’s heart failure therapy Verquvo now approved for use across Europe

Frank

WORLD – Verquvo, a drug developed for the treatment of symptomatic chronic heart failure has been cleared for use by the European Commission (EC). The approval reflects another important regulatory milestone in the development of the medicine which will provide doctors, health care professionals and patients with an important treatment option to complement currently available heart failure therapies. Merck and Bayer jointly co-developed Verquvo with Merck holding the commercial rights to the heart failure drug in the US and Bayer having exclusive commercial rights globally. The drug relayed successful data…

Read More

Boehringer Ingelheim’s Pradaxa approved by the FDA for oral pediatric use

Frank

USA – The Food and Drug Administration (FDA) has approved Boehringer Ingelheim’s Pradaxa as the first oral blood thinning medication suitable for children 12 years and below in the USA. The medication Pradaxa will be available for use for children with venous thromboembolism immediately after treatment with a blood thinner given by injection for at least five days. Venous thromboembolism (VTE) is a disorder that includes deep vein thrombosis and pulmonary embolism with deep vein thrombosis (DVT) occurring when a blood clot forms in a deep vein, usually in the…

Read More